Lux Bio initiates Ph I study of LX214
New Jesey, USA-based Lux Biosciences has begun treating patients in a Phase I study with its third product candidate, LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin. The company is developing the agent as a potential treatment for keratoconjunctivitis sicca, commonly known as dry eye syndrome, and other chronic inflammatory ocular surface diseases.
"We are pleased with the progress of our program for LX214, which we advanced from inception into the clinic in 18 months, in parallel with our LX211 and LX201 Phase III development programs," said Ulrich Grau, Lux' chief executive.
He noted that LX214 is a unique product that, based on preclinical data, is differentiated from the benchmark therapy by:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze